Colorectal Cancer – Pipeline Review, H2 2017: 3-V Biosciences Inc, 3SBio Inc, 4SC AG,AB Science SA

A new independent 1962 page research with title ‘Colorectal Cancer – Pipeline Review, H2 2017’  guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as 3-V Biosciences Inc, 3SBio Inc, 4SC AG, AB Science SA, AbbVie, etc… With n-number of tables and figures examining the Colorectal Cancer, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022

Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/871964-colorectal-cancer-pipeline-review-1

The latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer – Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 26, 110, 143, 11, 175, 29 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 20, 9, 33 and 4 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
– The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report

3-V Biosciences Inc,3SBio Inc,4SC AG,AB Science SA,AbbVie Inc,AbGenomics International Inc,Aclaris Therapeutics Inc,Adamed Sp z oo,Aduro BioTech Inc,Advenchen Laboratories LLC,AlfaSigma SpA,Allinky Biopharma,amcure GmbH,Amgen Inc,Amunix Operating Inc,Antibe Therapeutics Inc,APEIRON Biologics AG,Apexigen Inc,Aphios Corp,Aposense Ltd,Arisaph Pharmaceuticals Inc,ARMO Biosciences Inc,ArQule Inc,Array BioPharma Inc,Asana BioSciences LLC,Aslan Pharmaceuticals Pte Ltd,Astellas Pharma Inc,Astex Pharmaceuticals Inc,AstraZeneca Plc,Aurobindo Pharma Ltd,AVEO Pharmaceuticals Inc,B Cell Design SAS,Basilea Pharmaceutica Ltd,Bavarian Nordic A/S,Bayer AG,BeiGene Ltd,Beijing Hanmi Pharmaceutical Co Ltd,BeyondSpring Pharmaceuticals Inc,Biocon Ltd,Bionomics Ltd,Bionovis SA,Biotecnol Ltd,Biothera Pharmaceutical Inc,Boehringer Ingelheim GmbH,Boston Biomedical Inc,Bristol-Myers Squibb Co,Calithera Biosciences Inc,Cancer Prevention Pharmaceuticals Inc,Cantargia AB,Carna Biosciences Inc,Cascadian Therapeutics Inc,CBT Pharmaceuticals Inc,CCRP Therapeutics GmbH,Celgene Corp,Celldex Therapeutics Inc,Cellectar Biosciences Inc,Celleron Therapeutics Ltd,Celltrion Inc,Celyad SA,Chipscreen Biosciences Ltd,ChoDang Pharm Co Ltd,Chong Kun Dang Pharmaceutical Corp,Cleave Biosciences Inc,Cleveland BioLabs Inc,COARE Biotechnology Inc,Coherus BioSciences Inc,Compugen Ltd,Conatus Pharmaceuticals Inc,Corvus Pharmaceuticals Inc,Critical Outcome Technologies Inc,CrystalGenomics Inc,Daiichi Sankyo Co Ltd,DanDrit Biotech A/S,Deciphera Pharmaceuticals LLC,Dr. Reddy’s Laboratories Ltd,eFFECTOR Therapeutics Inc,Eisai Co Ltd,Eli Lilly and Co,Endor Nanotechnologies SL,Ensol Biosciences Inc,EntreChem SL,Enzene Biosciences Ltd,Enzo Biochem Inc,EpiThany Inc,Etubics Corp,Exelixis Inc,Exicure Inc,F-star Biotechnology Ltd,F. Hoffmann-La Roche Ltd,Fate Therapeutics Inc,Formosa Laboratories Inc,Forty Seven Inc,Fusion Antibodies Ltd,Gene Techno Science Co Ltd,Genentech Inc,Genor BioPharma Co Ltd,Genoscience Pharma,Genzyme Corp,Gilead Sciences Inc,GlaxoSmithKline Plc,Glenmark Pharmaceuticals Ltd,Glycostem Therapeutics BV,Glycotope GmbH,Green Cross Cell Corp,Green Cross Corp,Handok Inc,Hanmi Pharmaceuticals Co Ltd,Heat Biologics Inc,Heidelberg Pharma AG,Hemispherx Biopharma Inc,Humanigen Inc,Humorigin Biotechnology Corp,Hutchison MediPharma Ltd,iDD biotech SAS,Ideaya Biosciences Inc,Ignyta Inc,Ildong Pharmaceutical Co Ltd,Immodulon Therapeutics Ltd,ImmuneXcite Inc,Immunomedics Inc,Immunovative Therapies Ltd,Incanthera Ltd,Incyte Corp,Innovation Pharmaceuticals Inc,Innovent Biologics Inc,Inovio Pharmaceuticals Inc,Interprotein Corp,Intezyne Technologies Inc,Isofol Medical AB,Jeil Pharmaceutical Co Ltd,JHL Biotech Inc,Jiangsu Hengrui Medicine Co Ltd,Johnson & Johnson,Karyopharm Therapeutics Inc,Kazia Therapeutics Ltd,Kura Oncology Inc,Laboratorio ELEA SACIF y A,LipoMedix Pharmaceutical Inc,Loxo Oncology Inc,Luye Pharma Group Ltd,Mabion SA,MacroGenics Inc,Mantis Therapeutics BV,Marina Biotech Inc,Medesis Pharma SA,MediaPharma SRL,MedImmune LLC,Medivir AB,MELEMA Pharma GmbH,Merck & Co Inc,Merck KGaA,Merrimack Pharmaceuticals Inc,Merus NV,Microlin Bio Inc,Millennium Pharmaceuticals Inc,Moderna Therapeutics Inc,Molecular Partners AG,MolMed SpA,Mologen AG,Morphotek Inc,Multimmune GmbH,Mycenax Biotech Inc,NantKwest Inc,Natco Pharma Ltd,NatureWise Biotech & Medicals Corp,Nektar Therapeutics,Neovacs SA,Nerviano Medical Sciences Srl,Nippon Kayaku Co Ltd,NormOxys Inc,Northwest Biotherapeutics Inc,Novartis AG,Noxxon Pharma AG,NuCana Plc,OBI Pharma Inc,Omnitura Therapeutics Inc,Oncobiologics Inc,Oncology Research International Ltd,Oncolytics Biotech Inc,OncoMed Pharmaceuticals Inc,Onconova Therapeutics Inc,Ono Pharmaceutical Co Ltd,Otsuka Holdings Co Ltd,PDS Biotechnology Corp,Pfizer Inc,Pharma Mar SA,PharmAbcine Inc,Pivotal BioSciences Inc,PlantForm Corp,Plexxikon Inc,PLx Pharma Inc,Precision Biologics Inc,Propanc Biopharma Inc,Provectus Biopharmaceuticals Inc,PsiOxus Therapeutics Ltd,Puma Biotechnology Inc,Puretech Health plc,R Pharm,Rafael Pharmaceuticals Inc,RedHill Biopharma Ltd,Redx Pharma Plc,Rexahn Pharmaceuticals Inc,Rgenix Inc,Rhizen Pharmaceuticals SA,Richter Gedeon Nyrt,Samumed LLC,Sanofi,Selvita SA,Siamab Therapeutics Inc,Sichuan Kelun Pharmaceutical Co Ltd,Sigma-Tau SpA,Sigmoid Pharma Ltd,Sillajen Biotherapeutics,Simcere Pharmaceutical Group,Sino Biopharmaceutical Ltd,Sorrento Therapeutics Inc,Steba Biotech SA,Sumitomo Dainippon Pharma Co Ltd,Sun Pharma Advanced Research Company Ltd,SuviCa Inc,Symphogen A/S,Syndax Pharmaceuticals Inc,SynDevRx Inc,Synermore Biologics Co Ltd,Taiho Pharmaceutical Co Ltd,TaiwanJ Pharmaceuticals Co Ltd,Takeda Pharmaceutical Co Ltd,Targovax ASA,Tarrex Biopharma Ltd,Tarveda Therapeutics Inc,tella Inc,Theralase Technologies Inc,Tiltan Pharma Ltd,Tocagen Inc,TRACON Pharmaceuticals Inc,United BioPharma Inc,Vaccinex Inc,VasGene Therapeutics Inc,Vaximm AG,ViiV Healthcare UK Ltd,Vitality Biopharma Inc,Wellstat Biologics Corp,WntResearch AB,Wuhan YZY Biopharma Co Ltd,XBiotech Inc,XuanZhu Pharma Co Ltd,Zelluna Immunotherapy AS,Zymeworks Inc

Request a sample report @ https://www.htfmarketreport.com/sample-report/871964-colorectal-cancer-pipeline-review-1

Table of Contents
Table of Contents 2
Introduction 11
Colorectal Cancer – Overview 12
Colorectal Cancer – Therapeutics Development 13
Colorectal Cancer – Therapeutics Assessment 70
Colorectal Cancer – Companies Involved in Therapeutics Development 100
Colorectal Cancer – Drug Profiles 211
Colorectal Cancer – Dormant Projects 1872
Colorectal Cancer – Discontinued Products 1891
Colorectal Cancer – Product Development Milestones 1896
Appendix 1906List of Tables
Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Sta

….Continued

Place a Purchase Order for this Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=871964

Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
sales@htfmarketreport.com
Ph: +1 (206) 317 1218